Caveolin-1 (CAV-1) up regulation in metabolic syndrome: all roads leading to the same end
| Autor: | Maria Eduarda de Albuquerque Borborema, Dinaldo Cavalcanti de Oliveira, Jaqueline de Azevêdo Silva, Gabriela Montenegro de Souza, Brenda Regina de Lima, Thays Maria Costa de Lucena, Ariane Fernandes da Silva Santos |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty medicine.medical_treatment Caveolin 1 Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Insulin resistance Internal medicine Diabetes mellitus Genetics medicine Humans Obesity RNA Messenger Molecular Biology Aged Whole blood Metabolic Syndrome Analysis of Variance Cholesterol business.industry Insulin General Medicine Middle Aged medicine.disease Up-Regulation Cross-Sectional Studies 030104 developmental biology Gene Expression Regulation chemistry Case-Control Studies 030220 oncology & carcinogenesis Female Insulin Resistance Metabolic syndrome business Dyslipidemia |
| Zdroj: | Molecular Biology Reports. 47:9245-9250 |
| ISSN: | 1573-4978 0301-4851 |
| Popis: | Metabolic syndrome (MS) is a set of clinical conditions such as insulin resistance, hyperglycemia, systemic arterial hypertension (SAH), dyslipidemia, obesity and high abdominal circumference. Some of these clinical characteristics have been associated with caveolin-1, a caveolae structural protein, responsible for insulin activation, storage and degradation of cholesterol, and so on. Herein we assessed CAV-1 mRNA levels in MS patients comparing to healthy controls (HC) and according patients’ clinical features. We included 87 patients in the study, 25 patients with MS, 30 patients with at least one clinical condition (diabetes, SAH, dyslipidemia, obesity and high abdominal circumference), 13 with two clinical conditions and 19 HC. CAV-1 mRNA levels from peripheral blood samples were assessed by Real Time qPCR using specific Taqman probe. The analysis was performed using ∆Cq method and the statistical tests Shapiro–Wilk, One-Way ANOVA and Mann–Whitney. We found CAV-1 increased mRNA levels in patients with MS (1.645 FC, p = 9.794 × 10−20) and even higher in patients with only one or two clinical conditions (2.215 FC, p = 1.215 × 10−32 and 1.716 FC, p = 4.197 × 10−05, respectively). When individual clinical conditions were observed, individuals with high abdominal circumference and obesity present a significantly up regulation when compared to HC (2.956 FC, p = 0.0004 and 3.643 FC, p = 0.002, respectively). This work indicates that CAV-1 gene expression from whole blood samples is associated to MS clinical conditions and may become a potential target for MS treatment and prevention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink